Lucentis (ranibizumab)

Prescribing Information

Safety Data Sheets:

LUCENTIS^® Prefilled Syringes (0.5 mg/0.05 mL)

LUCENTIS^® Prefilled Syringe (0.3 mg/0.05 mL)

LUCENTIS^® Vials (0.3 mg/0.05 mL)

LUCENTIS^® Vials (0.5 mg/0.05 mL)

Healthcare Provider Letters:

Counterfeit Product - November 2018

Important Drug Notification: Intraocular Inflammatory Reactions After Intravitreal Injection - Dec 2008

SAILOR with AMD - Jan 2007

Safety Risk with Intravitreal Use of VEGF - Aug 2006

Publications and Congresses Clinical Trials Additional Resources

Publications

Visit PubMed.gov to browse a listing of published scientific literature about Lucentis^®.

Ranibizumab for neovascular age-related macular degeneration
Rosenfeld PJ, Brown DM, Heier JS, et al. N Engl J Med 2006;355:1419-1431.

VIEW

Ranibizumab versus verteporfin for neovascular age-related macular degeneration
Brown DM, Kaiser PK, Michels M, et al. N Engl J Med 2006;355:1432-1444.

VIEW

Ranibizumab versus verteporfin photodynamic therapy for neovascular age-related macular degeneration: Two-year results of the ANCHOR study
Brown DM, Michels M, Kaiser PK, et al. Ophthalmology 2009;116:57-65.

VIEW

Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 1
Regillo CD, Brown DM, Abraham P, et al. Am J Ophthalmol 2008;145:239-248.

VIEW

Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration
Busbee BG, Ho AC, Brown DM, et al. Ophthalmology 2013;120:1046-1056.

VIEW

Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration
Ho AC, Busbee BG, Regillo CD, et al. Ophthalmology 2014;121:2181-2192.

VIEW

RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia
Wolf S, Balciuniene VJ, Laganovska G, et al. Ophthalmology 2014;121:682-692.e2.

VIEW

Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE
Nguyen QD, Brown DM, Marcus DM, et al. Ophthalmology 2012;119:789-801.

VIEW

Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE
Brown DM, Nguyen QD, Marcus DM, et al. Ophthalmology 2013;120:2013-2022.

VIEW

Panretinal photocoagulation vs intravitreous ranibizumab for proliferative diabetic retinopathy: a randomized clinical trial
Gross JG, Glassman AR, Jampol LM, et al. JAMA 2015;314:2137-2146.

VIEW

Ranibizumab for macular edema following branch retinal vein occlusion: Six-month primary endpoint results of a phase III study
Campochiaro PA, Heier JS, Feiner L, et al. Ophthalmology 2010;117:1102-1112.

VIEW

Ranibizumab for macular edema following central retinal vein occlusion: six-month primary end point results of a phase III study
Brown DM, Campochiaro PA, Singh RP, et al. Ophthalmology 2010;117:1124-1133.e1.

VIEW

A Genentech Medical Science Liaison in your area can assist with medical questions about Lucentis^® and other Genentech products.

Connect with an MSL

Scientific Congresses

Genentech maintains a presence at in-person and virtual scientific congresses worldwide. Find Genentech-sponsored posters and presentations from recent congresses at Medically.gene.com.

November 2-5, 2022
Onsite